-
A randomized double-blind phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC)
The purpose of the study is to evaluate the efficacy and safety of NIS793 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo in ... -
Melanoma Margins Trial (MelMarT): A Phase III Multi-Centre Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma.
You can participate in this study if you are diagnosed with skin melanoma stage 2. This study will determine whether there is a difference in ... -
A Phase 3 Randomized Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (UpRi) as Post-Platinum Maintenance Therapy for Participants with Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT).
You can participate in this study if you are diagnosed with Platinum-Sensitive Recurrent Ovarian Cancer. In this study we will evaluate the study drug (Upifitamab ... -
EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence.
You can participate in this study if you are diagnosed with ER+, HER2- Early Breast Cancer (Stages I-III) with an Increased Risk of Recurrence. And ... -
A Phase 3 Open-Label Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Push Compared with Intravenous Amivantamab or Subcutaneous Amivantamab Administered via On Body Delivery System in Patients with EGFR-Mutated Advanced or Metastatic Non-Small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy.
You can participate in this study if you are diagnosed with advanced lung cancer. The purpose of this study is to know the efficacy and ...